Cited by 340Immune Response and InflammationInflammasome and immune disordersImmune responses and vaccinations

The DOI matches its Crossref record; the references it cites are not checked yet.

Soluble Forms of Toll-Like Receptor (TLR)2 Capable of Modulating TLR2 Signaling Are Present in Human Plasma and Breast Milk

Open access
LeBouder, Emmanuel, Rey-Nores, Julia E, Rushmere, Neil K, Grigorov, Martin, Lawn, Stephen D, Affolter, Michael, Griffin, George E, Ferrara, Pascual, Schiffrin, Eduardo J, Morgan, B Paul, Labéta, Mario O·2003·The Journal of Immunology

Abstract

Dysregulation of the initial, innate immune response to bacterial infection may lead to septic shock and death. Toll-like receptors (TLRs) play a crucial role in this innate immune response, and yet the regulatory mechanisms controlling microbial-induced TLR triggering are still to be fully understood. We have therefore sought specific regulatory mechanisms that may modulate TLR signaling. In this study, we tested for the possible existence of a functionally active soluble form of TLR2. We demonstrated the existence of natural soluble forms of TLR2 (sTLR2), which we show to be capable of modulating cell activation. We found that blood monocytes released sTLR2 constitutively and that the kinetics of sTLR2 release increased upon cell activation. Analysis of cells expressing the human TLR2 cDNA or its c-myc-tagged version indicated that sTLR2 resulted from the posttranslational modification of the TLR2 protein in an intracellular compartment. Moreover, an intracellular pool of sTLR2 is maintained. sTLR2 was found naturally expressed in breast milk and plasma. Milk sTLR2 levels mirrored those of the TLR coreceptor soluble CD14. Depletion of sTLR2 from serum resulted in an increased cellular response to bacterial lipopeptide. Notably, serum sTLR2 was lower in tuberculosis patients. Coimmunoprecipitation experiments and computational molecular docking studies showed an interaction between sTLR2 and soluble CD14 in plasma and milk. These findings suggest the existence of a novel and specific innate immune mechanism regulating microbial-induced TLR triggering, and may lead to new therapeutics for the prevention and/or treatment of severe infectious diseases.

Overview

Integrity signals

Registry

Crossref · 10.4049/jimmunol.171.12.6680

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Soluble forms of TLR2 and TLR4 function as decoys competing with membrane-bound TLRs for ligand binding.

    “soluble forms of TLR2 and TLR4 have been identified to function as decoy, competing with the membrane-bound forms of TLRs for ligands binding [123, 124]”

Citations

The citation lists haven’t been fetched yet

References 46 · Cited by 340

Research works printed but not linked: 45

  1. 1994, Clin. Infect. Dis., S205
  2. 1992, Chest, 1644
  3. 2001, Crit. Care Med., S8
  4. 2001, Nat. Rev., 135
  5. 2002, Curr. Opin. Immunol., 103
  6. 1999, J. Biol. Chem., 33419
  7. 2002, Curr. Top. Microbiol. Immunol., 121
  8. 2002, J. Virol., 8729
  9. 2001, J. Biol. Chem., 21129
  10. 1999, Science, 732
  11. 1999, J. Immunol., 1
  12. 1996, Immunity, 407
  13. 1986, Eur. J. Immunol., 1583
  14. 1994, Eur. J. Immunol., 2006
  15. 1992, J. Exp. Med., 1665
  16. 2000, J. Exp. Med., 1807
  17. 2001, Proc. Natl. Acad. Sci. USA, 603
  18. 2002, Biochim. Biophys. Acta, 1
  19. 1998, J. Leukocyte Biol., 135
  20. 2001, Trends Immunol., 328
  21. 2000, Clin. Exp. Immunol., 483
  22. 1993, Eur. J. Immunol., 2144
  23. 1995, Current Protocols in Protein Science, 12.5.3
  24. 1999, Eur. J. Immunol., 265
  25. 1998, J. Immunol., 3924
  26. 2002, J. Immunol. Methods, 245
  27. 1999, RECOMB 99: Proceedings of the Third Annual Conference on Computational Molecular Biology, April 11–14, 218, 10.1145/299432.299486 · DOI
  28. 1998, J. Mol. Biol., 519
  29. 2001, J. Mol. Biol., 807
  30. 1992, Proc. Natl. Acad. Sci. USA, 2195
  31. 1988, J. Am. Chem. Soc., 1657
  32. 2001, J. Leukocyte Biol., 474
  33. 1999, J. Immunol., 639
  34. 1990, Biochim. Biophys. Acta, 225
  35. 1999, Nature, 811
  36. 2001, Pediatr. Res., 589
  37. 2000, Proc. Natl. Acad. Sci. USA, 6043
  38. 2000, J. Biol. Chem., 24255
  39. 2002, Blood, 1860
  40. 2000, J. Immunol., 3476
  41. 2000, Proc. Natl. Acad. Sci. USA, 13766
  42. 2001, Int. Immunol., 933
  43. 1999, Science, 736
  44. 2001, J. Immunol., 6682
  45. 2002, J. Biol. Chem., 24315

Metadata

Authors
LeBouder, E., Rey-Nores, J. E., Rushmere, N. K., Grigorov, M., Lawn, S. D., Affolter, M., Griffin, G. E., Ferrara, P., Schiffrin, E. J., Morgan, B. P., & Labéta, M. O.
Affiliations
  • Section of Infection and Immunity, University of Wales, College of Medicine , Cardiff ,
  • Cardiff University (GB)
  • Nestlé (Switzerland) (CH)
  • St George's Hospital (GB)
  • Sanofi (France) (FR)
Venue
The Journal of Immunology
Published
2003-12
Volume
171
Issue
12
Pages
6680-6689
ISSN
  • 0022-1767 (ISSN-L)
  • 1550-6606
OpenAlex
W2122065046
Cited by
340
References
46
Citations by year
2026: 5 · 2025: 4 · 2024: 5 · 2023: 14 · 2022: 6 · 2021: 14 · 2020: 7 · 2019: 11 · 2018: 14 · 2017: 9 · 2016: 14 · 2015: 21 · 2014: 23 · 2013: 21 · 2012: 19
FWCI
4.85
Type
journal article
Language
en
Open access
Locations
  • The Journal of Immunology (publishedVersion)
  • PubMed (publishedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (submittedVersion)
Funders
Sanofi
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
  • Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
Keywords
soluble CD14, breast milk, plasma, monocytes, post-translational modification, lipopeptides, tuberculosis, innate immunity, septic shock, bacterial infection
MeSH terms
Amino Acid Sequence, Cell Line, Cell Membrane, Cells, Cultured, Cysteine, Female, Humans, Immunoglobulin Fc Fragments, Intracellular Fluid, Lactation, Lipoproteins, Macrophage Activation, Membrane Glycoproteins, Milk, Human, Molecular Sequence Data, Monensin, Monocytes, Peptides, Precipitin Tests, Protein Processing, Post-Translational, Receptors, Cell Surface, Recombinant Fusion Proteins, Solubility, Signal Transduction, Down-Regulation, DNA, Complementary, Lipopolysaccharide Receptors, Protein Isoforms, Protein Transport, Toll-Like Receptors, Toll-Like Receptor 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review